Apr 06, 2016
Novartis makes partnership with the International Committee of the Red Cross (ICRC) for improving treatment and care for Syrian refugees in Lebanon who are suffering from chronic diseases.
In Lebanon, half of the population does not have any type of health coverage, and the refugee crisis has placed an extra burden on medical facilities already struggling. These refugees face difficulties accessing medicines, diagnosis, and ongoing care. Novartis and the International Committee of the Red Cross (ICRC) are partnering to improve treatment and care for the most vulnerable people in Lebanon. The main goal is to establish a blueprint to improve diagnosis, treatment and follow-up of Lebanese and also the refugees who are suffering from chronic diseases.
Novartis has decided to provide medicines for diabetes and high blood pressure. These diseases together account for more than 50% of deaths in Lebanon every year. The medicines are being supplied through Novartis Access, a program focusing on availability and affordability of on- and off-patent medicines addressing key non-communicable diseases. These medicines are offered to public-sector healthcare providers and governments at a price of USD 1 per treatment per month in lower and lower-middle-income countries.
As said by Rodolfo Rossi, health coordinator at the ICRC in Lebanon: “Non-communicable diseases are on the rise, not only in the Middle East but worldwide. This will give the ICRC the opportunity to receive drugs for non-communicable diseases at a very preferential price, allowing us to include more patients.”